- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03393221
Improving Emotion Regulation Skills Among Adolescents Attempting to Lose Weight
Enhancing Emotion Regulation Among Overweight and Obese Adolescents Attempting to Lose Weight
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Rhode Island
-
Providence, Rhode Island, États-Unis, 02903
- Coro Building
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- 13-17 years of age
- > 85th percentile for BMI but < a BMI of 50
- speak English
- agree to participation and randomization
Exclusion Criteria:
- they are currently in another weight loss program
- have a medical condition that precludes participation in physical activity or adherence to dietary recommendations
- are developmentally delayed such that the intervention will not be appropriate
- are in treatment for a major psychiatric disorder.
- cannot understand English
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: SBWC+ER
Participants randomized to the Standard Behavioral Weight Control and Emotional Regulation (SBWC+ER) condition receive a 14-session intervention that is comprised of 12 consecutive weekly sessions and 2 booster sessions delivered at weeks 14 and 16.
They receive the same information as the Standard Behavioral Weight Control group, but weekly sessions also include elements of TRAC, and it is designed to help teach emotion regulation skills to decrease overeating and sedentary behaviors and increase the likelihood of maintaining diet and exercise behaviors that are taught as part of SBWC interventions.
|
Emotion regulation content
|
|
Comparateur actif: SBWC
Participants randomized to the Standard Behavioral Weight Control (SBWC) condition receive a 14-session intervention that is comprised of 12 consecutive weekly sessions and 2 booster sessions delivered at weeks 14 and 16.
The intervention includes a dietary plan, a fitness plan, behavioral weight control management that includes self-monitoring, goal-setting, stimulus control strategies, and planning, as well as parental involvement.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
BMI decrease
Délai: baseline, 4 months, and 8 month follow up
|
A significant decrease in participant BMI due to weight loss
|
baseline, 4 months, and 8 month follow up
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Emotion Regulation
Délai: baseline, 4 month, and 8 month follow up
|
Difficulties in Emotion Regulation Scale (DERS)- a 36-item questionnaire designed to assess multiple aspects of emotion regulation (scale: 1 strongly disagree- 5 strongly agree).
Measure yields a total score as well as six scales derived through factor analysis: (1.
Nonacceptance of emotional response, 2. Difficulties engaging in goal directed behavior [goals], 3. Impulse control difficulties [impulse], 4. Lack of emotion awareness [awareness], 5. Limited access to emotion regulation strategies [strategies] 6. Lack of emotional clarity [clarity] ).
|
baseline, 4 month, and 8 month follow up
|
|
Emotion Regulation Strategy Usage
Délai: baseline, 4 month, and 8 month follow up
|
Emotion Regulation Behavior Scale (ERBS)- assesses use of emotion regulation strategies taught in intervention.
items include "in the last week, when you were having a strong feeling (e.g., sad, upset, etc.) how often did you...get away from whatever was causing your feeling?..."participants respond on a scale of 1 (never) to 5 (all the time) across 8 items, with higher scores indicating more regulatory behaviors (range: 8-40)
|
baseline, 4 month, and 8 month follow up
|
|
Emotion Regulation
Délai: baseline, 4 month, and 8 month follow up
|
Affect Dysregulation Scale (ADS)- 24 item scale adapted from the clinician-rated Affect Regulation and Experience q-sort questionnaire, modified with 6-items used to assess frequency of difficulty with affect regulation on 4-point Likert, with higher scores indicating more difficulty with affect (range: 6-36)
|
baseline, 4 month, and 8 month follow up
|
|
Emotion Regulation
Délai: baseline, 4 month, and 8 month follow up
|
Toronto Alexithymia Scale (TAS)- "20 item instrument that is one of the most commonly used measures of alexithymia. Alexithymia refers to people who have trouble identifying and describing emotions and who tend to minimize emotional experience and focus attention externally. 3 subscales: 1-difficulty describing emotions (5 items-2,4,11,12,17), 2- difficulty identifying emotions (7 items-1,3,6,7,9,13,14), and 3- the tendency of individuals to focus their attention externally (8 items-5,8,10,15,16,18,19,20) " (Likert scale: 1 completely disagree - 5 completely agree) (Total range: 20-200) |
baseline, 4 month, and 8 month follow up
|
|
Distress Tolerance
Délai: baseline and 4 months
|
Behavior Indicator of Resiliency to Distress (BIRD)- Manipulation/measure of distress-tolerance.
The first level of the BIRD test lasts 3 minutes.
The level begins with a 5 second latency between dot presentations and changes this latency based on performance (correct answers will reduce the latency by 0.5 seconds whereas incorrect answers or non-responses increase the latency by 0.5 seconds).
At the conclusion of this level an average latency is calculated to index skill level.
The second level lasts five total minutes.
Following a brief rest period the final level begins and lasts for 5 minutes.
At all points in the final level the participant will have an escape option.
The "quit game" on the screen can be clicked at any time.
Therefore making the total time for this game roughly 10-15 minutes long.
(Amstadter et al, 2011)
|
baseline and 4 months
|
|
Emotion Regulation
Délai: baseline, 4 month, and 8 month follow up
|
Emotions as a Child scale- "examines parental emotional socialization from both parent and child perspectives across 45-items.
This measure generates 5 subscales of emotion socialization including parental encouragement of emotion expression, parental punishing of responses, parental neglect, parental matching, and parental overriding of child's emotions.
Reliability of subscales range from .80 to .87"
|
baseline, 4 month, and 8 month follow up
|
|
Emotion Regulation
Délai: baseline, 4 month, and 8 month follow up
|
Emotion Regulation Checklist (ERC)- "is an instrument for the hetero-evaluation of the level of emotion regulation of children by means of two scales, Emotion Regulation (ER) and Emotional Lability/ Negativity.
24 items that are assessed on a four point Likert scale (1=never, 2=sometimes, 3=often, and 4= almost always).
The ERC comprises two scales: one scale contains 8 items to assess ER, while the other scale contains 15 items that measure emotional liability/negativity, including lack of flexibility, emotional activation, reactivity, anger dysregulation, and mood reliability.
(L/N α = .96;
ER α = .83),
and the two scales are significantly correlated (r = -.50, p < .001).
One single measurement of ER is generated from the overall scores in both sub-scales (α = .89;
Shields & Cicchetti, 1997)."
|
baseline, 4 month, and 8 month follow up
|
|
Emotional Eating
Délai: baseline, 4 month, and 8 month follow up
|
Emotional Eating Scale (EES)- "25 item self report measure used to assess the propensity to cope with negative affect by eating.
Subjects rate their desire to eat in response to each emotion on 5 point scale from "1"I have no desire to eat"" through "5"I have a very strong desire to eat""" (Range 25- 125, with higher scores indicating more coping with affect by eating)
|
baseline, 4 month, and 8 month follow up
|
|
Eating Disorders
Délai: baseline, 4 month, and 8 month follow up
|
Eating Disorder Examination Questionnaire (EDEQ)- " 28 item questionnaire that has 2 additional questions for males and 5 additional questions for females.
Used to measure eating disorder psychopathology, with higher scores indicating higher eating disorder psychopathy.
Provides a measure of the range and severity of eating disorder features.
Also has the ability to generate operational eating disorder diagnoses.
Used to screen potential participants [Subscales: Restraint (items 1,2,3,4,5), Eating concern (items 7,9,19,20,21), Shape concern (items 6,8,10,11,23,26,27,28), Weight Concern (8,12,22,24,25) ]
|
baseline, 4 month, and 8 month follow up
|
|
Eating Habits Confidence
Délai: baseline to 8 months
|
Eating Habits Confidence Questionnaire (EHCQ)- "27-item scale questionnaire asks participants to rate confidence in their ability to adhere to specific dietary behaviors.
Response set consisted of a 5 point-linkert type scale ranging from 1, ""I know I cannot"" to 5, ""I know I can.""
Possible scores of this survey range from 27 to 135, with higher scores indicating higher self-efficacy.
|
baseline to 8 months
|
|
Eating Behavior
Délai: baseline, 4 months, and 8 months
|
Eating Behaviors Inventory- "Instrument for assessing behaviors that have been theoretically implicated in weight loss (self monitoring of food intake and of weight, refusing offers of food, eating at only one place, shopping from a list) 30 items are included that are each rate with a 5 point scale according to how often it was true for the respondent.
Items were scored such that the higher scores always reflected more appropriate eating patterns."
(Total range: 30- 150)
|
baseline, 4 months, and 8 months
|
|
Accelerometer (physical activity)
Délai: baseline and 4 months
|
Majority of studies say at least 5 days per week for at least 8 hours per day to receive accurate data on PA.
Device used to measure physical activity using criteria such as time spent in activities performed for various intensities and for the prediction of energy expenditure.
|
baseline and 4 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Wendy Hadley, PhD, University of Oregon
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 1R21DK108164-01A1 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Surpoids et obésité
-
Ivoclar Vivadent AGComplétéCaries Pit and Fissure Limité à l'émailAllemagne, Suisse
-
Mathematica Policy Research, Inc.Boston Children's Hospital; Department of Health and Human ServicesPas encore de recrutementIntervention précoce, éducation (Head Start et Early Head Start Access and Participation)États-Unis
-
Bambino Gesù Hospital and Research InstituteComplétéObésité pédiatrique sévère (IMC > 97° pc -Selon les Centers for Disease Control and Prevention BMI Charts-) | Tests de la fonction hépatique altérée | Intolérance glycémiqueItalie
-
Tanta UniversityActif, ne recrute pasPerte osseuse, alvéolaire | Ridge Augmentaton and Dental ImplantsEgypte
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)RecrutementCarcinome épidermoïde de la tête et du cou | Stage IV Head and Nou Cartane cutané CARCINOMA SELLES A AJCC V8 | Stade III Tête et cou CARCINOME SPÉLIQUE CUDAME AUJCC V8 | Étape I tête et cou cutané cutané carcinome squameux AJCC V8 | Stage II CARCINOME SPÉLÉE CURTANÉE II A AJCC V8États-Unis
-
AstraZenecaActif, ne recrute pasAdv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian CancerÉtats-Unis, France, Royaume-Uni, Corée du Sud
-
NRG OncologyNational Cancer Institute (NCI)SuspenduCarcinome oropharyngé de stade clinique III médié par le VPH (p16 positif) AJCC v8 | Carcinome oropharyngé de stade clinique IV médié par le VPH (p16 positif) AJCC v8 | Carcinome oropharyngé de stade III (p16-négatif) AJCC v8 | Carcinome oropharyngé de stade IV (p16-négatif) AJCC v8 | Carcinome... et d'autres conditionsÉtats-Unis, Canada, Hong Kong, Suisse, Irlande
-
National Cancer Institute (NCI)SuspenduStage IV Head and Nou Cartane cutané CARCINOMA SELLES A AJCC V8 | Stade III Tête et cou CARCINOME SPÉLIQUE CUDAME AUJCC V8 | Carcinome épidermoïde des paupières | Carcinome épidermoïde acantholytique de la peau | Carcinome épidermoïde à cellules claires de la peau | Carcinome lymphoépithélial... et d'autres conditionsÉtats-Unis, Australie, Canada
-
National Cancer Institute (NCI)RecrutementCarcinome épidermoïde récurrent de la tête et du cou | Carcinome épidermoïde hypopharyngé récurrent | Carcinome épidermoïde laryngé récurrent | Carcinome épidermoïde récurrent de la cavité buccale | Carcinome épidermoïde oropharyngé récurrent | Carcinome épidermoïde métastatique de la tête... et d'autres conditionsÉtats-Unis
-
National Cancer Institute (NCI)Actif, ne recrute pasCarcinome épidermoïde récurrent de la tête et du cou | Carcinome épidermoïde hypopharyngé récurrent | Carcinome épidermoïde laryngé récurrent | Carcinome épidermoïde métastatique de la tête et du cou | Carcinome oropharyngé de stade clinique IV médié par le VPH (p16 positif) AJCC v8 | Carcinome... et d'autres conditionsÉtats-Unis
Essais cliniques sur ER
-
RVL Pharmaceuticals, Inc.Osmotica Pharmaceutical US LLCRetiréSclérose en plaques | SpermeÉtats-Unis
-
TaiRx, Inc.Complété
-
Uppsala UniversityRecrutementTDAH | Régulation des émotions | Trouble déficitaire de l'attention avec hyperactivitéSuède
-
Jewish General HospitalComplété
-
Medical University of South CarolinaGeorgia State UniversityComplétéTroubles anxieux | Troubles de stress, post-traumatique | Désordre mental | Trouble de stress traumatiqueÉtats-Unis
-
Chang Gung Memorial HospitalTianjin Medical University Cancer Institute and Hospital; Shanghai Chest HospitalRecrutementCarcinome épidermoïde de l'œsophageTaïwan
-
Columbia UniversityBiolase IncComplété
-
Asieris Pharmaceuticals (AUS) Pty Ltd.Complété
-
The Cleveland ClinicAmneal Pharmaceuticals, LLCRecrutementMaladie de ParkinsonÉtats-Unis
-
National Institute of Mental Health (NIMH)ComplétéPharmacocinétique | AdulteÉtats-Unis